The global acute kidney injury (AKI) treatment market is poised for remarkable growth, registering a compound annual growth rate (CAGR) of 8.2% from 2022 to 2029. In 2022, the market is anticipated to hold a valuation of USD 2,058.2 million and is projected to reach an impressive USD 3,566.7 million by the end of 2029.
This growth is being driven by the increasing prevalence of acute kidney injury worldwide, which is largely associated with rising incidences of chronic conditions such as diabetes and hypertension. The growing aging population and increased awareness of kidney health are also contributing to the demand for advanced AKI treatment options.
Acute Kidney Injury, a sudden loss of kidney function that can occur due to a variety of causes including injury, infection, or complications from other conditions, presents a significant healthcare challenge. The growing prevalence of this condition globally, combined with the introduction of advanced treatment modalities and supportive technologies, is driving market growth.
Industry experts attribute this robust market trajectory to several factors, including increased investment in research and development, enhanced diagnostic and monitoring technologies, and a surge in the number of patients requiring specialized care. Furthermore, the rise in geriatric populations and chronic diseases that predispose individuals to AKI are expected to further fuel demand for effective treatment solutions.
Key Takeaways:
- Owing to increasing acute kidney injury prevalence, number of dialysis centres, and efficient treatment method, the dialysis segment is expected to be a significant revenue generator.
- The intermittent haemodialysis segment, under product, in the acute kidney injury treatment market, is expected to be a prominent segment, as results provided by this treatment are more efficient as compared to other dialysis methods.
- The pre-renal injury segment is anticipated to dominate the acute kidney injury treatment market, as pre-renal injury is more prevalent in patients with acute kidney injury.
- North America is expected to dominate the global acute kidney injury treatment market in terms of revenue, owing to the growing adoption of advanced treatments over conventional methods. East Asia is expected to offer lucrative opportunities for the acute kidney injury treatment market during the forecast period.
Advanced Technology & Product Launches – Key Strategies Followed by Manufacturers
The participants in the acute renal injury treatment market are keeping up with advances in diagnostic technology and increased product availability in order to streamline their product offerings in respective regions with different product portfolios. For example, Fresenius Medical Care introduced the 4008A dialysis equipment in January 2022 in an effort to provide accessibility to dialysis treatment that is life-sustaining.
Competitive Landscape:
To provide patients with cutting-edge care, major companies in the worldwide acute renal injury treatment market are concentrating on creating automated, mobile, and tech-driven dialysis equipment. In order to broaden their range of products, they are also using cutting-edge technology like artificial intelligence and the Internet of Things (IoT).
In the meantime, several of the other firms are developing diagnostic technologies to simplify their product offers in emerging markets where their product portfolios are diversified.
For instance:
- In March 2021, C-Path announced the launch of an acute kidney injury project in partnership with the USA Food and Drug Administration (FDA) for Drug Evaluation and Research, the Office of translational science, and the Division of cardiology and Nephrology, to develop a suite of prognostic tools to improve the detection of drug-induced kidney injury.
- In June 2021, Abionyxx announced the enrollment of the first patient in its Phase-2a clinical study with CER-001 for the treatment of septic patients at high risk of developing acute kidney injury.
Key Companies Profiled:
- Novartis, Pfizer Inc.
- Merck & Co.
- Biocon Ltd.
- Teva Pharmaceutical Industries Ltd.
- Mylan Pharmaceuticals Inc.
- NIPRO Medical
- Baxter Corporation
- Asahi Kasei
- NIKKISO
- Fresenius Medical Care
- Others
A Old Full Report Analysis Click Here
Acute Kidney Injury Treatment Market By Category:
Product:
- Dialysis
- Intermittent Hemodialysis
- Continuous Renal Replacement Therapy (CRRT)
- Sustained Low-Efficiency Dialysis (SLED)
- Drug Therapy
- Antibiotics
- Diuretics
- Immunosuppressive Agents
Injury:
- Pre-renal Injury
- Intrinsic Renal Injury
- Post-renal Injury
Distribution Channel:
- Hospitals
- Ambulatory Surgical Centers
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
